XBiotech Announces Payment of Dividend to Holders of Common Stock
2021年7月31日 - 12:03AM
XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) has completed payment to
holders of its Common Stock of a previously announced dividend in
the amount of USD$75,000,000.00. Based on the number of shares of
Common Stock issued and outstanding on the record date for the
dividend, each such holder received USD$2.47 per share on July 23,
2021.
In the past 18 months, XBiotech’s balance sheet strength has
enabled the company to offer approximately USD$495 million in cash
to shareholders by way of stock repurchase and dividend
distribution. The financial strength of the Company owes to the
successful development of a pipeline of True Human™ antibody drug
candidates.
John Simard stated that “XBiotech was pleased to be able to
reward its shareholders with a $2.47 per share dividend. Our
ability to continue to provide opportunities for shareholders to
monetize stock in XBiotech, reflects the strength of our
fundamental approach to our industry. It begins with a visionary
strategy to create a drug pipeline from natural human
immunity—which offers an array of exceptional candidate
therapeutics. Proprietary manufacturing technology developed at
XBiotech has reduced our capital outlays needed for producing drug
product, enabling us to build a drug development infrastructure
debt-free. Integrating clinical operations has allowed us to
conduct our own clinical trials, to test our breakthrough
therapies, for a fraction of the cost of the standard industry
approach, which involves the use of expensive clinical research
contractors. Finally, from our manufacturing technology and
clinical operations, we have generated contract revenue that has
largely offset operating costs over the past two years. In short,
we have stayed the course with our science and pushed the
boundaries of industry practices to develop breakthrough therapies,
reduce costs and create returns for our shareholders. We have never
been more excited about our pipeline and opportunities than we are
today.” About True Human™ Therapeutic
AntibodiesXBiotech’s True Human™ antibodies are derived
without modification from individuals who possess natural immunity
to certain diseases. With discovery and clinical programs across
multiple disease areas, XBiotech’s True Human™ antibodies have the
potential to harness the body’s natural immunity to fight disease
with increased safety, efficacy and tolerability.About
XBiotechXBiotech is a fully integrated global biosciences
company dedicated to pioneering the discovery, development and
commercialization of therapeutic antibodies based on its True
Human™ proprietary technology. XBiotech currently is advancing a
robust pipeline of antibody therapies to redefine the standards of
care in oncology, inflammatory conditions and infectious diseases.
Headquartered in Austin, Texas, XBiotech is also leading the
development of innovative biotech manufacturing technologies
designed to more rapidly, cost-effectively and flexibly produce
therapies urgently needed by patients worldwide. For more
information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking
Statements This press release contains
forward-looking statements, including declarations regarding
management's beliefs and expectations that involve substantial
risks and uncertainties. In some cases, you can identify
forward-looking statements by terminology such as "may," "will,"
"should," "would," "could," "expects," "plans," "contemplate,"
"anticipates," "believes," "estimates," "predicts," "projects,"
"intend" or "continue" or the negative of such terms or other
comparable terminology, although not all forward-looking statements
contain these identifying words. Forward-looking statements are
subject to inherent risks and uncertainties in predicting future
results and conditions that could cause the actual results to
differ materially from those projected in these forward-looking
statements. These risks and uncertainties are subject to the
disclosures set forth in the "Risk Factors" section of certain of
our SEC filings. Forward-looking statements are not guarantees of
future performance, and our actual results of operations, financial
condition and liquidity, and the development of the industry in
which we operate, may differ materially from the forward-looking
statements contained in this press release. Any forward-looking
statements that we make in this press release speak only as of the
date of this press release. We assume no obligation to update our
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Contact
Kaitlyn Hopkinskhopkins@xbiotech.comTel. 737-207-4600
XBiotech (NASDAQ:XBIT)
過去 株価チャート
から 12 2024 まで 1 2025
XBiotech (NASDAQ:XBIT)
過去 株価チャート
から 1 2024 まで 1 2025